Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis
Table 3
Prognostic factor analysis for progression-free survival and overall survival (matched).
Variable
Overall survival
Progression-free survival
Univariate analysis
Multivariate analysis
Univariate analysis
Multivariate analysis
HR (95% CI)
HR (95% CI)
HR (95% CI)
HR (95% CI)
Treatment type
0.65 (0.451-0.947)
0.018
0.60 (0.409-0.887)
0.010
0.70 (0.485-1.018)
0.045
0.67 (0.453-0.977)
0.038
Age (years)
1.05 (0.700-1.587)
0.801
0.94 (0.621-1.435)
0.788
Cirrhosis clinical course
1.04 (0.619-1.748)
0.882
1.08 (0.640-1.810)
0.782
Child-Pugh class
2.41 (1.162-5.001)
0.018
1.97 (0.941-4.138)
0.072
2.33 (1.123-4.840)
0.023
1.93 (0.913-4.067)
0.085
ALB grade
0.95 (0.913-0.991)
0.017
3.11 (1.488-6.502)
0.003
0.96 (0.915-0.996)
0.032
2.12 (1.018-4.407)
0.045
ECOG PS
0.87 (0.595-1.260)
0.453
0.90 (0.616-1.315)
0.586
Portal vein invasion stage
1.10 (0.819-1.482)
0.523
1.08 (0.807-1.449)
0.600
Extrahepatic spread
1.20 (0.826-1.748)
0.337
1.16 (0.797-1.686)
0.439
Tumor diameter
0.967 (0.667-1.401)
0.859
0.85 (0.586-1.238)
0.400
AFP
1.14 (0.788-1.656)
0.482
1.05 (0.721-1.517)
0.813
ALB: albumin; HR: hazard ratio; OS: overall survival; PFS: progression-free survival; AFP: serum α-fetoprotein level. Data in parentheses are 95% confidence intervals. A Cox proportional hazard regression model for PFS and OS was used.
